{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:01:43Z","timestamp":1790262103937,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":339,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1002\/rth2.12657","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T02:54:45Z","timestamp":1644288885000},"page":"e12657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12657_bb0010","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential thrombocythemia","volume":"381","author":"Tefferi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12657_bb0015","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0020","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1002\/rth2.12657_bb0025","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","article-title":"Polycythemia vera: historical oversights, diagnostic details, and therapeutic views","volume":"35","author":"Tefferi","year":"2021","journal-title":"Leukemia"},{"key":"10.1002\/rth2.12657_bb0030","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome\u2010negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1002\/rth2.12657_bb0035","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1002\/rth2.12657_bb0040","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk\u2010stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12657_bb0045","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0050","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/JBM.S189922","article-title":"Polycythemia vera\u2010associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"10","author":"Cuthbert","year":"2019","journal-title":"J Blood Med"},{"key":"10.1002\/rth2.12657_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population\u2010based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12657_bb0060","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12657_bb0065","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12657_bb0075","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO\u2010defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0080","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12657_bb0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"Guglielmelli","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1002\/rth2.12657_bb0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-020-0290-9","article-title":"The new WHO classification for essential thrombocythemia calls for revision of available evidences","volume":"10","author":"Barbui","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1002\/rth2.12657_bb0095","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jth.14754","article-title":"Association between myelofibrosis and thromboembolism: a population\u2010based retrospective cohort study","volume":"18","author":"Saliba","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12657_bb0100","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3324\/haematol.2017.182303","article-title":"Impact of hydroxycarbamide and interferon\u2010\u03b1 on red cell adhesion and membrane protein expression in polycythemia vera","volume":"103","author":"Brusson","year":"2018","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12657_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222944","article-title":"Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures","volume":"14","author":"Singer","year":"2019","journal-title":"PLoS One"},{"key":"10.1002\/rth2.12657_bb0110","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta\u2010analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12657_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-019-0225-5","article-title":"Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm\u2010associated thrombosis: a consensus\u2010based position paper","volume":"9","author":"Barbui","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1002\/rth2.12657_bb0120","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"Carobbio","year":"2010","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0125","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez\u2010Larr\u00e1n","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12657_bb0135","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/s41375-018-0199-5","article-title":"Evidence\u2010 and consensus\u2010based recommendations for phlebotomy in polycythemia vera","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1002\/rth2.12657_bb0140","unstructured":"National Comprehensive Cancer Network (NCCN). Myeloproliferative Neoplasms (version 2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf Accessed September 21, 2021."},{"key":"10.1002\/rth2.12657_bb0145","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1002\/rth2.12657_bb0150","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit\u2010risk profile of hydroxyurea in polycythemia vera: a propensity\u2010matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12657_bb0155","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3324\/haematol.2019.221234","article-title":"Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta\u2010analysis","volume":"104","author":"Ferrari","year":"2019","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12657_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-018-0161-9","article-title":"Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1002\/rth2.12657_bb0165","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12657_bb0170","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","article-title":"Anagrelide: a new drug for treating thrombocytosis","volume":"318","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12657_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high\u2010risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12657_bb0180","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO\u2010classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long\u2010term observational study of 3649 high\u2010risk patients in the Evaluation of Anagrelide Efficacy and Long\u2010term Safety study","volume":"103","author":"Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12657_bb0190","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high\u2010risk features","volume":"36","author":"Godfrey","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12657_bb0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low\u2010risk thrombocythaemia: results from a prospective study","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12657_bb0200","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1002\/rth2.12657_bb0205","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12657_bb0210","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta\u2010analysis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1002\/rth2.12657_bb0215","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3390\/cancers12071954","article-title":"Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature","volume":"12","author":"How","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1002\/rth2.12657_bb0220","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long\u2010term effects of the treatment of polycythemia vera with recombinant interferon\u2010alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"key":"10.1002\/rth2.12657_bb0230","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon\u2010alfa\u20102a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0235","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera\u2010a systematic review and meta\u2010analysis","volume":"35","author":"Bewersdorf","year":"2021","journal-title":"Leukemia"},{"key":"10.1002\/rth2.12657_bb0240","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa\u20102b versus standard therapy for polycythaemia vera (PROUD\u2010PV and CONTINUATION\u2010PV): a randomised, non\u2010inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1002\/rth2.12657_bb0245","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12185-021-03171-1","article-title":"Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta\u2010analysis","volume":"114","author":"Gu","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1002\/rth2.12657_bb0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low\u2010dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12657_bb0255","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review","volume":"167","author":"Chu","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12657_bb0260","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low\u2010risk essential thrombocythemia","volume":"116","author":"Alvarez\u2010Larr\u00e1n","year":"2010","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0265","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low\u2010risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez\u2010Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12657_bb0270","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.1002\/ajh.26137","article-title":"Extreme thrombocytosis in low\u2010risk essential thrombocythemia: retrospective review of vascular events and treatment strategies","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12657_bb0275","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2352-3026(21)00204-0","article-title":"Unmet clinical needs in the management of CALR\u2010mutated essential thrombocythaemia: a consensus\u2010based proposal from the European LeukemiaNet","volume":"8","author":"Alvarez\u2010Larr\u00e1n","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1002\/rth2.12657_bb0280","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase\u20101 and \u20102 to persistent thromboxane biosynthesis in aspirin\u2010treated essential thrombocythemia: implications for antiplatelet therapy","volume":"115","author":"Dragani","year":"2010","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0285","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-018-0078-3","article-title":"The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1002\/rth2.12657_bb0290","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double\u2010blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"key":"10.1002\/rth2.12657_bb0295","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","article-title":"Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia","volume":"94","author":"Hern\u00e1ndez\u2010Boluda","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1002\/rth2.12657_bb0300","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00277-018-3483-6","article-title":"High risk of recurrent venous thromboembolism in BCR\u2010ABL\u2010negative myeloproliferative neoplasms after termination of anticoagulation","volume":"98","author":"Wille","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1002\/rth2.12657_bb0305","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"De Stefano","year":"2016","journal-title":"Leukemia"},{"key":"10.1002\/rth2.12657_bb0310","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1002\/ajh.23809","article-title":"Cerebral vein thrombosis in patients with Philadelphia\u2010negative myeloproliferative neoplasms. An European Leukemia Net study","volume":"89","author":"Martinelli","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12657_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1002\/rth2.12657_bb0320","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1002\/rth2.12657_bb0325","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1002\/rth2.12657_bb0330","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long\u2010term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta\u2010analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12657_bb0335","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/rth2.12657_bb0340","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"10.1002\/rth2.12657_bb0345","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"Hamuly\u00e1k","year":"2021","journal-title":"Blood Adv"},{"issue":"Suppl 2","key":"10.1002\/rth2.12657_bb0350","first-page":"245","article-title":"Circulating biologic markers of endothelial dysfunction in chronic myeloproliferative neoplasms [abstract]","volume":"5","author":"Smirnova","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1002\/rth2.12657_bb0355","first-page":"262","article-title":"Endothelial dysfunction in patients with Ph\u2010negative myeloproliferative neoplasms [abstract]","volume":"5","author":"Korsakova","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1002\/rth2.12657_bb0360","first-page":"830","article-title":"Effect of therapy on thrombin generation in patients with polycythemia vera [abstract]","volume":"5","author":"Silina","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1002\/rth2.12657_bb0365","first-page":"827","article-title":"Endothelial dysfunction in patients with polycythemia vera on cytoreductive and\/or antiplatelet therapy [abstract]","volume":"5","author":"Silina","year":"2021","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12657","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922011189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922011189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:22:48Z","timestamp":1762863768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922011189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2475037922011189"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12657","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}],"article-number":"e12657"}}